Lee Ainslie Rocket Pharmaceuticals, Inc. Transaction History
Maverick Capital LTD
- $5.08 Billion
- Q1 2025
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Maverick Capital LTD holds 5,199,218 shares of RCKT stock, worth $15 Million. This represents 0.68% of its overall portfolio holdings.
Number of Shares
5,199,218
Previous 5,198,900
0.01%
Holding current value
$15 Million
Previous $65.4 Million
46.93%
% of portfolio
0.68%
Previous 1.26%
Shares
15 transactions
Others Institutions Holding RCKT
# of Institutions
258Shares Held
108MCall Options Held
555KPut Options Held
177K-
Rtw Investments, LP New York, NY17.7MShares$50.9 Million1.93% of portfolio
-
Wellington Management Group LLP Boston, MA12.6MShares$36.4 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$19.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$17.8 Million0.0% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.82MShares$13.9 Million0.17% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $218M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...